University of Utah at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

University of Utah takes part in 3 sessions at CTAD 2026 in Boston. Its program centres on who benefits from and who is harmed by anti-amyloid treatment. Its work covers CSF markers that predict ARIA with lecanemab, blood pressure control by APOE genotype and cognitive paths in patients with co-pathology.

OrganizationCTAD 2026 Attendance
University of Utah
Salt Lake City, Utah
Poster
Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue
Poster
Wed Nov 18
7:15am–5:30pm
Baseline CSF p-tau181/Ab42 ratio predicts ARIA risk in lecanemab patients (P299)
Blood and CSF biomarkers · Anti-amyloid and anti-tau therapies
Poster
Thu Nov 19
7:15am–5:00pm
Divergent cognitive trajectories in patients with suspected co-pathology receiving lecanemab (P507)
Anti-amyloid and anti-tau therapies · Real-world data and access

Explore the full CTAD 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Boston. Leave your work email and we’ll be in touch.

Privacy

Download the full CTAD 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from University of Utah

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction